Tag: alzheimers drug

Shares of biotech giant Biogen were falling on Wednesday after the company said it would delay the submitting of its Alzheimer’s treatment, aducanumab, for Food and Drug Administration approval. The company said it expects to finish submission for aducanumab by the end of the third quarter now. This will likely delay and put an FDA … Continue reading “Biogen Tumbles After Delay of Alzheimer’s Treatment Submission”